2022
DOI: 10.1016/j.ijcha.2022.101070
|View full text |Cite
|
Sign up to set email alerts
|

Socioeconomic disparities in use of rhythm control therapies in patients with incident atrial fibrillation: A Finnish nationwide cohort study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

3
4

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 25 publications
0
5
0
Order By: Relevance
“… 60 A nationwide study in 188 175 patients with AF from Finland reported lower use of rhythm control procedures including cardioversions, use of antiarrhythmic drugs, and ablations in those with the lowest incomes. 61 A study in 2 236 580 patients with AF from the UK reported that individuals from minoritized racial and low SES groups underwent fewer catheter ablations for AF. 62 …”
Section: Resultsmentioning
confidence: 99%
“… 60 A nationwide study in 188 175 patients with AF from Finland reported lower use of rhythm control procedures including cardioversions, use of antiarrhythmic drugs, and ablations in those with the lowest incomes. 61 A study in 2 236 580 patients with AF from the UK reported that individuals from minoritized racial and low SES groups underwent fewer catheter ablations for AF. 62 …”
Section: Resultsmentioning
confidence: 99%
“…Finally, the higher prevalence of cardiovascular comorbidities and lower income in rural areas likely impact the clinical decision making of AATs, although these factors were controlled for in our adjusted analyses. Indeed, low income has been previously associated with lower use of rhythm control therapies [ 28 ].…”
Section: Discussionmentioning
confidence: 99%
“…Exclusion criteria encompassed permanent emigration abroad before 31 December 2018, and age below 20 years at AF diagnosis. The present sub‐study was conducted within a cohort of patients with incident AF from 2007 to 2018, established in previous studies of the FinACAF cohort 25,27,28 . Follow‐up started from the initial AF diagnosis and continued until the initiation of OAC therapy, death or 31 December 2018, whichever came first.…”
Section: Methodsmentioning
confidence: 99%